Circadian disruption and breast cancer: From melatonin to clock genes

Epidemiology

Volumn 16, Issue 2, 2005, Pages 254-258

  Stevens, Richard G ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASEIN KINASE I; CRYPTOCHROME 1; ESTROGEN; GENE PRODUCT; MELATONIN; PER1 PROTEIN; PROTEIN BMAL1;

APOPTOSIS; BMAL1 GENE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER RISK; CELL CYCLE; CIRCADIAN RHYTHM; CK1E GENE; CLOCK GENE; CRY1 GENE; CRY2 GENE; ENVIRONMENTAL FACTOR; ESTROGEN SYNTHESIS; GENE; GENE FUNCTION; GENETIC SUSCEPTIBILITY; HUMAN; PER1 GENE; PER2 GENE; PER3 GENE; PRIORITY JOURNAL; REVIEW; SUPRACHIASMATIC NUCLEUS;

BREAST NEOPLASMS; CELL CYCLE; CIRCADIAN RHYTHM; EPIDEMIOLOGIC STUDIES; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LIGHT; MELATONIN; PHOTOPERIOD; RISK FACTORS;

EID: 14644415433     PISSN: 10443983     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ede.0000152525.21924.54     Document Type: Review

References (60)

1. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000: the global picture. Eur J Cancer. 2001;37:S4-S66.
2. Nagata C, Kawakami N, Shimizu H. Trends in the incidence rate and risk factors for breast cancer in Japan. Breast Cancer Res Treat. 1997;44:75-82.
3. Stevens RG. Review and commentary: electric power use and breast cancer: a hypothesis. Am J Epidemiol. 1987;125:556-561.
4. Stevens RG, Rea MS. Light in the built environment: potential role of circadian disruption in endocrine disruption and breast cancer. Cancer Causes Control. 2001;12:279-287.
5. Fu L, Lee CC. The circadian clock: pacemaker and tumor suppressor. Nature Rev Cancer. 2003;3:350-361.
6. Cole RJ, Kripke DF, Wisbey J, et al. Seasonal variation in human illumination exposure at two different latitudes. J Biol Rhythm. 1995; 10:324-334.
7. Wehr TA. Photoperiodism in humans and other primates: evidence and implications. J Biol Rhythm. 2001;16:348-364.
8. Czeisler CA, Duffy JF, Shanahan TL, et al. Stability, precision, and near-24-hour period of the human circadian pacemaker. Science. 1999; 284:2177-2181.
9. Cohen M, Lippman M, Chabner B. Role of the pineal gland in the aetiology and treatment of breast cancer. Lancet. 1978;2:814-881.
10. Brzezinski A. Melatonin in humans. N Engl J Med. 1997;336:186-195.
11. Lewy AJ, Wehr TA, Goodwin FK, et al. Light suppresses melatonin secretion in humans. Science. 1980;210:1267-1269.
12. Brainard GC, Hanifin JP, Greeson JM, et al. Action spectrum for melatonin regulation in humans: evidence for a novel circadian photoreceptor. J Neurosci. 2001;21:6405-6412.
13. Lockley SW, Brainard GC, Czeisler CA. High sensitivity of the human circadian melatonin rhythm to resetting by short wavelength light. J Clin Endocrinol Metab. 2003;88:4502-4505.
14. Blask DE, Pelletier DB, Hill SM, et al. Pineal melatonin inhibition of tumor promotion in the N-nitroso-N-methylurea model of mammary carcinogenesis: potential involvement of antiestrogenic mechanisms in vivo. J Cancer Res Clin Oncol. 1991;117:526-532.
15. Shah PN, Mhatre MC, Kothari LS. Effect of melatonin on mammary carcinogenesis in intact and pinealectomized rats in varying photoperiods. Cancer Res. 1984;44:3403-3407.
16. Anderson LE, Morris JE, Sasser LB, et al. Effect of constant light on DMBA mammary tumorigenesis in rats. Cancer Letters. 2000;148:121-126.
17. Russo IH, Russo J. Mammary gland neoplasia in long-term rodent studies. Environ Health Perspect. 1996;104:938-967.
18. Blask DE, Dauchy RT, Sauer LA, et al. Growth and fatty acid metabolism of human breast cancer (MCF-7) xenografts in nude rats: impact of constant light-induced nocturnal melatonin suppression. Breast Cancer Res Treat. 2003;79:313-320.
19. Stevens RG, Davis S, Thomas DB, et al. Electric power, pineal function, and the risk of breast cancer. FASEB J. 1992;6:853-860.
20. Hahn RA. Profound bilateral blindness and the incidence of breast cancer. Epidemiology. 1991;2:208-210.
21. Tynes T, Hannevik M, Andersen A, et al. Incidence of breast cancer in Norwegian female radio and telegraph operators. Cancer Causes Control. 1996;7:197-204.
22. Hansen J. Increased breast cancer risk among women who work predominantly at night. Epidemiology. 2001;12:74-77.
23. Davis S, Mirick DK, Stevens RG. Night shift work, light at night, and risk of breast cancer. J Natl Cancer Inst. 2001;93:1557-1562.
24. Schernhammer ES, Laden L, Speizer FE, et al. Rotating night shifts and risk of breast cancer in women participating in the Nurses' Health Study. J Natl Cancer Inst. 2001;93:1563-1568.
25. Feyschting M, B Österlund B, Ahlbom A. Reduced cancer incidence among the blind. Epidemiology. 1998;9:490-494.
26. Verkasalo PK, Pukkala E, Stevens RG, et al. Inverse association between breast cancer incidence and degree of visual impairment in Finland. Br J Cancer. 1999;80:1459-1460.
27. Kliukiene J, Tynes T, Andersen A. Risk of breast cancer among Norwegian women with visual impairment. Br J Cancer. 2001;84:397-399.
28. Pukkala E, Auvinen A, Wahlberg G. Incidence of cancer among Finnish airline cabin attendants, 1967-92. BMJ. 1995;311:649-652.
29. Schemhammer ES, Rosner B, Willett WC, et al. Epidemiology of urinary melatonin in women and its relation to other hormones and night work. Cancer Epidemiol Biomark Prev. 2004;13:936-943.
30. Travis RC, Allen DS, Fentiman IS, et al. Melatonin and breast cancer: a prospective study. J Natl Cancer Inst. 2004;96:475-482.
31. Menaker M. Circadian photoreception. Science. 2003;299:213-214.
32. Czeisler CA, Shanahan TL, Klerman EB, et al. Suppression of melatonin in some blind patients by exposure to bright light. N Engl J Med. 1995;331:6-11.
33. Yoshimura T, Ebihara S. Spectral sensitivity of photoreceptors mediating phase-shifts of circadian rhythms in retinally degenerate CBA/J (rd/rd) and normal CBA/N (+/+) mice. J Comp Physiol A. 1996;178: 797-802.
34. Lucas RJ, Freedman M, Muñoz M, et al. Regulation of the mammalian pineal by non-rod, non-cone, ocular photoreceptors. Science. 1999;284: 505-507.
35. Lockley SW, Skene DJ, Arendt J, et al. Relationship between melatonin rhythms and visual loss in the blind. J Clin Endocrinol Metab. 1997; 82:3763-3770.
36. Van Gelder RN. Making (a) sense of non-visual ocular photoreception. Trends Neurosci. 2003;26:458-461.
37. Panda S, Antoch MP, Miller BH, et al. Coordinated transcription of key pathways in the mouse by the circadian clock. Cell. 2002;109:307-320.
38. Zheng B, Larkin DW, Albrecht U, et al. The mPer2 gene encodes a functional component of the circadian clock. Nature. 1999;400:169-173.
39. Fu L, Pelicano H, Liu J, et al. The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell. 2002;111:41-50.
40. Filipski E, King VM, Li XM, et al. Host circadian clock as a control point in tumor progression. J Natl Cancer Inst. 2002;94:690-697.
41. Johansson C, Willeit M, Smedh C, et al. Circadian clock-related polymorphisms in seasonal affective disorder and their relevance to diurnal preference. Neuropsychopharmacology. 2003;28:734-739.
42. Katzenberg D, Young T, Finn L, et al. A clock polymorphism associated with diurnal preference. Sleep. 1998;21:569-576.
43. Horne JA, Östberg O. A self assessment questionnaire to determine morningness-eveningness in human circadian rhythms. Int J Chronobiol. 1976;4:97-110.
44. Archer SN, Robilliard DL, Skene DJ, et al. A length polymorphism in the circadian clock gene Per3 is linked to delayed sleep phase syndrome and extreme diurnal preference. Sleep. 2003;26:413-415.
45. Griefahn B, Künemund C, Golka K, et al. Melatonin synthesis: a possible indicator of intolerance to shiftwork. Am J Indus Med. 2002; 42:427-436.
46. Griefahn B. The validity of the temporal parameters of the daily rhythm of melatonin levels as an indicator of momingness. Chrono Int. 2002; 19:561-577.
47. MacMahon B. Cohort fertility and increasing breast cancer incidence. Cancer. 1958;11:250-254.
48. Stevens RG, Moolgavkar SH, Lee JAH. Temporal trends in breast cancer. Am J Epidemiol. 1982;115:759-777.
49. Trichopoulos D. Hypothesis: does breast cancer originate in utero? Lancet. 1990;335:939-940.
50. Potischman N, Troisi R. In utero and early life exposures in relation to risk of breast cancer. Cancer Causes Control. 1999;10:561-573.
51. Hamilton AS, Mack TM. Puberty and genetic susceptibility to breast cancer in a case-control study in twins. N Engl J Med. 2003;348:2313-2322.
52. Cohn BA, Cirillo PM, Christianson RE, et al. Placental characteristics and reduced risk of maternal breast cancer. J Natl Cancer Inst. 2001; 93:1133-1140.
53. Hill SM, Spriggs LL, Simon MA, et al. The growth inhibitory action of melatonin on human breast cancer cells is linked to the estrogen system. Cancer Lett. 1992;64:249-256.
54. Kiefer T, Ram PT, Yuan L, et al. Melatonin inhibits estrogen receptor transactivation and cAMP levels in breast cancer cells. Breast Cancer Res Treat. 2002;71:37-45.
55. Blask DE, Wilson ST, Zalatan F. Physiological melatonin inhibition of human breast cancer cell growth in vitro. Evidence for a glutathione-mediated pathway. Cancer Res. 1997;57:1909-1914.
56. Maestroni GJ. Therapeutic potential of melatonin in immunodeficiency state, viral diseases, and cancer. Adv Exp Med Biol. 1999;467:217-226.
57. Reiter RJ, Tan DX. Melatonin: an antioxidant in edible plants. Ann N Y Acad Sci. 2002;957:341-344.
58. Zhu Y, Brown HN, Zhang Y, et al. Period3 structural variation: a circadian biomarker associated with breast cancer in young women. Cancer Epidemiol Biomark Prev. In press.
59. Ebisawa T, Kajimura N, Uchiyama M, et al. Allelic variants of human melatonin 1a receptor: function and prevalence in subjects with circadian rhythm sleep disorders. Biochem Biophys Res Comm. 1999;262: 832-837.
60. Earnest DJ, Chen WJA, West JR. Developmental alcohol and circadian clock function. Alcohol Res Health. 2001;25:136-140.